Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population

References

• Anoop S, Misra A, Meena K, Luthra K. 2010. Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. Indian J Med Res 132:363–378
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265
   Google Scholar
• Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, et al. 2005. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111:278–287
   PubMed Web of Science ®Google Scholar
• Branco CC, Palla R, Lino S, Pacheco PR, Cabral R, De Fez L, Peixoto BR, Mota-Vieira L. 2006. Assessment of Azorean ancestry by Alu insertion polymorphisms. Am J Hum Biol 18:223–226
   PubMed Web of Science ®Google Scholar
• Branco CC, São Bento M, Gomes CT, Cabral R, Pacheco PR, Mota-Vieira L. 2008. Azores Islands: genetic origin, gene flow and diversity patterns. Ann Hum Biol 35:65–74
   PubMed Web of Science ®Google Scholar
• Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, Noel M, Salit J, et al. 2008. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon 13. Arterioscler Thromb Vasc Biol 28:2078–2084
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Austin MA, Thummel KE. 2014. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. [Epub ahead of print]. doi: 10.1038/gim.2014.41
   Google Scholar
• Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridke PM. 2004. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821–2827
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, Morris AD, Donnan PT, Palmer CN. 2008. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: A GoDARTS study. Pharmacogenet Genomics 18:1021–1026
   PubMed Web of Science ®Google Scholar
• Drögemöller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, Koen L, et al. 2013. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet 4:17
   PubMedGoogle Scholar
• Excoffier L, Laval G, Schneider S. 2005. Arlequin ver. 3.0: An integrated software package for population genetics data analysis. Evol Bioinformat Online 1:47–50
   Google Scholar
• Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. Nature 343:425–430
   PubMed Web of Science ®Google Scholar
• Joseph PG, Pare G, Ross S, Roberts R, Anand SS. 2014. Pharmacogenetics in cardiovascular disease: The challenge of moving from promise to realization: Concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. Clin Cardiol 37:48–50
   Google Scholar
• Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. 1998. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 338:86–93
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, et al, SEARCH Collaborative Group. 2008. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359:789–799
   PubMed Web of Science ®Google Scholar
• Medina MW, Sangkuhl K, Klein TE, Altman RB. 2011. PharmGKB: very important pharmacogene—HMGCR. Pharmacogenet Genomics 21:98–101
   PubMed Web of Science ®Google Scholar
• Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. 2009. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 29:1310–1315
   PubMed Web of Science ®Google Scholar
• Mota-Vieira L, Pacheco PR, Almeida ML, Cabral R, Carvalho J, Branco CC, de Fez L, Peixoto BR, Araújo AL, Mendonça P. 2005. Human DNA bank in São Miguel Island (Azores), a resource for genetic diversity studies. In: Amorim A, Côrte-Real F, Morling N, editors. Progress in forensic genetics proceedings, vol. 1288. Amsterdam: Elsevier BV. p 388–390
   Google Scholar
• Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ. 1995. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy. Atherosclerosis 113:157–166
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873–879
   PubMed Web of Science ®Google Scholar
• Pavlovic S, Zukic B, Nikcevic G. 2012. Pharmacogenomics of thiopurine S-methyltransferase: Clinical applicability of genetic variants. In: Sanoudou D, editor. Clinical applications of pharmacogenetics. Rijeka, Croatia: InTech. p 75–94
   Google Scholar
• Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. 2010. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 29:629–37
   PubMed Web of Science ®Google Scholar
• Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, van der Graaf Y, et al. 2008. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: An adverse pharmacogenetic interaction. Eur Heart J 29:2792–2799
   PubMed Web of Science ®Google Scholar
• Rodrigues MO, Fonseca A, Matias Dias C, Albergaria I, Martins G, Alpendre ML, Martins Mdo C. 2005. APOE genotypes and dyslipidemias in a sample of the Portuguese population. Clin Chem Lab Med 43:907–912
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Pena SD, Struchiner CJ, Hutz MH. 2012. Pharmacogenomic diversity among Brazilians: Influence of ancestry, self-reported color, and geographical origin. Front Pharmacol 3:191
   PubMed Web of Science ®Google Scholar
• Superko HR, Momary KM, Li Y. 2012. Statins personalized. Med Clin N Am 96:123–139
   PubMed Web of Science ®Google Scholar
• Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, et al. 2005. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5:352–358
   PubMed Web of Science ®Google Scholar
• Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. 2009. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54:1609–1616
   PubMed Web of Science ®Google Scholar
• Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC). 2012. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 92:112–117
   PubMed Web of Science ®Google Scholar